Background: Diabetic macular edema (DME) has been reported at rates of 10% and occurs more frequently in type 2 diabetes mellitus. The present study was conducted to assess the efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. Materials & Methods: 60 patients with type 2 diabetes having treatment naïve, center‑involving DME of both genders were divided into 2 groups. Group I had DME only in one eye and group II had DME in both eyes. Group I were given oral fenofibrate 160 mg/day for 6 months as a single evening dose. Central macular thickness in both groups was compared